New York, May 24, 2026, 11:10 EDT
- Surgery Partners finished the session Friday at $13.40, moving in a range from $13.21 to $13.50.
- Nasdaq will be shut Monday for Memorial Day. Trading picks back up with the usual session on Tuesday.
- The last big update from the company was the first-quarter report on May 5, where it stuck with its 2026 guidance.
Surgery Partners stock finished the week lower, with a late Friday uptick failing to claw back early-week losses ahead of the long U.S. holiday weekend.
Surgery Partners Inc. shares finished at $13.40 on May 22, higher than Thursday’s close but trailing the $13.92 mark from Monday. Volume hit 967,747 shares Friday, according to the company’s LSEG-based stock data.
Nasdaq won’t have its normal Monday session as the market shuts for Memorial Day on May 25. That means traders lose the usual Monday reset. Usual trading hours stay at 9:30 a.m. to 4 p.m. Eastern.
The next test is Tuesday, when it will be clearer if the Friday rebound was just bargain hunting or if investors keep selling a stock still stuck near recent lows after a rough month.
Surgery Partners, based in Brentwood, Tennessee, updated investors with new operating numbers on May 5. The company stuck to its 2026 revenue forecast, looking for between $3.35 billion and $3.45 billion, and kept its adjusted EBITDA view at no less than $530 million. Adjusted EBITDA removes interest, taxes, depreciation, amortization and some other items.
First-quarter revenue was up 4.5% at $810.9 million. Same-facility revenue added 4.4%. But same-facility cases only increased 0.6%.
Surgery Partners CEO Eric Evans said in the release the company had a “solid start to 2026.” CFO Dave Doherty said these results “reinforce our confidence” in the outlook for the full year. Surgery Partners Inc.
Evans told the earnings call that first-quarter case growth was “modest,” blaming weather for disruption in lower-acuity markets. Chief Operating Officer Justin Oppenheimer said there are “real” tailwinds for the sector. Evans warned that acquisition spending timing can be “fickle.” Investing
Surgery Partners’ quarterly numbers spelled out the squeeze. Adjusted EBITDA dropped 1.5% to $102.3 million. Interest expense climbed to $69.1 million. The company posted a net loss of $35.9 million attributable to Surgery Partners.
Healthcare-facilities stocks traded mixed Friday. HCA Healthcare added 0.4%. Tenet Healthcare dropped 2.4%, and Universal Health Services slipped 2.9%. Smaller surgery-center stocks got little direction from peers.
Analysts are still backing the stock. According to MarketScreener, 12 analysts have a Buy rating. The average price target stands at $17.95, while the shares closed last at $13.40.
The risks are clear. If procedure growth doesn’t pick up, payor mix leans to lower-margin cases, or interest costs keep taking a toll on cash flow, investors may want more evidence before buying into the company’s 2026 targets. The company warned bigger economic trends could weigh on payor mix, patient counts and collections.
Surgery Partners heads into the week needing to keep shares above $13 after the holiday. The main question is if gains in revenue per case and tighter costs are offsetting slower case growth.
